Ardelyx (ARDX) Rated as ‘Overweight’ at Cantor Fitzgerald amid Ibsrela Sales Growth Expectation

Ardelyx Inc. (NASDAQ:ARDX) is one of the penny stocks that will skyrocket. On July 7, analysts at Cantor Fitzgerald reiterated an ‘Overweight’ rating on the stock. The positive stance stems from expectations that the company is well-positioned for robust growth, backed by its flagship product, Ibsrela.

Ardelyx (ARDX) Rated as ‘Overweight’ at Cantor Fitzgerald amid Ibsrela Sales Growth Expectation

Cantor Fitzgerald expects Ibsrela to exceed consensus sales expectations in the second quarter. The research firm expects Ardelyx to deliver $64 million in sales, significantly higher than the $57 million consensus estimate. Amid the expected robust sales growth, the research firm views the 2025 Ibsrela guidance of $240-$250 million as conservative, given the strong prescription trends.

While Xphozah, another flagship product, is expected to miss sales estimates, Cantor Fitzgerald anticipates that it will have a limited impact on current valuation levels. Cantor Fitzgerald maintains that expectations for Xphozah are already lower than consensus.

Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative first-in-class medicines to address significant unmet medical needs, particularly in kidney and cardiovascular diseases.

While we acknowledge the potential of ARDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARDX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Best AI Stocks to Buy According to Billionaire Stanley Druckenmiller and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty.

Disclosure: None. This article is originally published at Insider Monkey.